{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:52:04Z","timestamp":1793710324779,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40644-019-0218-4","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T10:03:05Z","timestamp":1559210585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience"],"prefix":"10.1186","volume":"19","author":[{"given":"Christoph","family":"Artzner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Mossakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Hefferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Grosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Syha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Gr\u00f6zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"218_CR1","doi-asserted-by":"crossref","first-page":"175883401875717","DOI":"10.1177\/1758834018757175","volume":"10","author":"J Yang","year":"2018","unstructured":"Yang J, et al. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:1758834018757175.","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"218_CR2","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881\u20135.","journal-title":"Ophthalmology"},{"issue":"11","key":"218_CR3","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"218_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005;123(12):1639\u201343.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"218_CR5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D, et al. Prognosis of mucosal, uveal, Acral, Nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist. 2016;21(7):848\u201354.","journal-title":"Oncologist"},{"key":"218_CR6","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1200\/JCO.2016.34.15_suppl.9567","volume":"34","author":"L Khoja","year":"2016","unstructured":"Khoja L, et al. Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: an irci-ocular melanoma initiative. J Clin Oncol. 2016;34(15_suppl:9567.","journal-title":"J Clin Oncol"},{"issue":"5","key":"218_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","volume":"119","author":"The Collaborative Ocular Melanoma Study, G","year":"2001","unstructured":"The Collaborative Ocular Melanoma Study, G. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms): coms report no. 15. Arch Ophthalmol. 2001;119(5):670\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"218_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cncr.28480","volume":"120","author":"SS Agarwala","year":"2014","unstructured":"Agarwala SS, et al. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120(6):781\u20139.","journal-title":"Cancer"},{"issue":"3","key":"218_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00432-006-0155-z","volume":"133","author":"T Vogl","year":"2007","unstructured":"Vogl T, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133(3):177\u201384.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"218_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1080\/0284186X.2018.1465587","volume":"57","author":"S Tulokas","year":"2018","unstructured":"Tulokas S, et al. Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience. Acta Oncol. 2018;57(10):1373\u201380.","journal-title":"Acta Oncol"},{"issue":"4","key":"218_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","volume":"26","author":"ME Valsecchi","year":"2015","unstructured":"Valsecchi ME, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol. 2015;26(4):523\u201332 e2.","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"218_CR12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jvir.2018.04.030","volume":"29","author":"J Zheng","year":"2018","unstructured":"Zheng J, et al. Combined effects of Yttrium-90 Transarterial Radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series. J Vasc Interv Radiol. 2018;29(10):1369\u201375.","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"218_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1055\/s-0034-1366081","volume":"186","author":"TJ Vogl","year":"2014","unstructured":"Vogl TJ, et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo. 2014;186(10):937\u201344.","journal-title":"Rofo"},{"issue":"6","key":"218_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","volume":"40","author":"TJ Vogl","year":"2017","unstructured":"Vogl TJ, et al. Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-Centre study. Cardiovasc Intervent Radiol. 2017;40(6):864\u201372.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"218_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jso.23501","volume":"109","author":"MR Forster","year":"2014","unstructured":"Forster MR, et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014;109(5):434\u20139.","journal-title":"J Surg Oncol"},{"issue":"4","key":"218_CR16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available Care for Patients with melanoma liver metastases. Ann Surg Oncol. 2016;23(4):1309\u201319.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"218_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jso.24956","volume":"117","author":"I Karydis","year":"2018","unstructured":"Karydis I, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117(6):1170\u20138.","journal-title":"J Surg Oncol"},{"issue":"4","key":"218_CR18","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","volume":"29","author":"S Marquardt","year":"2019","unstructured":"Marquardt S, et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol. 2019;29(4):1882\u201392.","journal-title":"Eur Radiol"},{"issue":"2","key":"218_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"6","key":"218_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","volume":"42","author":"T. Susanna Meijer","year":"2019","unstructured":"Meijer TS, et al. Safety of percutaneous hepatic perfusion with Melphalan in patients with Unresectable liver metastases from ocular melanoma using the Delcath Systems\u2019 second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol. 2019;42(6):841\u201352. \n                    https:\/\/doi.org\/10.1007\/s00270-019-02177-x\n                    \n                  . Epub 2019 Feb 14.","journal-title":"CardioVascular and Interventional Radiology"},{"issue":"5","key":"218_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/sj.clpt.6100336","volume":"83","author":"A Kuhne","year":"2008","unstructured":"Kuhne A, et al. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther. 2008;83(5):749\u201357.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-019-0218-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40644-019-0218-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-019-0218-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:13:48Z","timestamp":1590693228000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-019-0218-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["218"],"URL":"https:\/\/doi.org\/10.1186\/s40644-019-0218-4","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This was a HIPAA compliant, IRB approved, retrospective study with waiver of informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable due to retrospective character of the study with full anonymization and waiver of informed consent by local IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}